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unavailability of EUS (1) and physician preference (6) . Therefore, the final group of patients comprised 147 consecutive patients. In 6 of these 147 patients, ERCP was attempted first without success. The mean age was 69.4 years (age range: 26 -91) and 62% of the patients were men. Ninety-six patients (65%) had malignancy as the cause of jaundice (mainly pancreatic cancers).
Study design
This was a diagnostic study that was based on a case series of patients who received EUS evaluation as the first diagnostic approach. Information on the centres where the study was conducted was not reported. The patients were prospectively followed until a definitive diagnosis was made. One endosonographer performed the diagnostic EUS and any subsequent EUS-guided FNA. The same endoscopist performed ERCP if it was indicated after EUS. Survival data were also assessed for a tumour registry. Once the final outcome and therapy of each patient was known, the course of each patient's evaluation was re-assessed assuming that, instead of EUS, ERCP was the first endoscopic procedure performed. No patient was lost to the follow-up assessment.
Analysis of effectiveness
The analysis of effectiveness was conducted on all patients in whom EUS was the first endoscopic approach taken. The outcomes used were: the success of EUS, the number of procedures performed, the outcomes of EUS patients, the diagnostic results of ERCP performed after an initial EUS evaluation, and survival.
Effectiveness results
Initial EUS was successful in all 147 patients and 54% of those patients who had EUS-FNA as part of their evaluation.
Seventy-four patients had a positive diagnosis of malignancy, which was confirmed when the procedure was performed.
One patient (0.7%) was misdiagnosed by the EUS-first approach.
Eighty-three patients had an ERCP within 90 days of the EUS.
Five ERCPs were confirmatory and none of them demonstrated additional findings.
Of the remaining 78 patients, ERCP provided additional useful information in 14 of them (17%), although the information obtained was clearly superior in only 2 of these 14 patients.
The EUS findings were clearly superior to those of ERCP in 20 patients.
Similar results were observed in 51 patients.
Of the 64 patients with pancreatic cancer, 37 had operations (25 resections and 12 bypasses) where operability could be assessed surgically.
Four patients had metastatic liver disease confirmed by EUS-FNA.
Four patients had resectable tumours by EUS, but were then deemed inoperable because of major co-morbidity or extreme age. Nineteen patients who were considered by EUS criteria to have unresectable tumours had a median survival of 158 days (range: 11 -283).
If ERCP were performed as first strategy (and using some of the literature-based assumptions reported below), there would have been 80 ERCPs more than when using EUS as the first diagnostic procedure but 20 EUS and 31 EUS-FNA would not have been performed. However, because of the initial diagnostic results, a significant number of post-ERCP procedures (including EUS or occasionally exploratory laparotomy) would have been required.
Clinical conclusions
The effectiveness analysis showed that EUS-FNA correctly identified the cause of obstructive jaundice in all but one patient (also missed by ERCP and operation). In addition, the total number of patients needing ERCP was reduced by 47%.
Outcomes assessed in the review
The outcomes assessed from the literature were assumptions about patient management.
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Eleven primary studies were used to support some of the assumptions made in the analysis.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
If a patient was found to have a biliary stricture at ERCP, then a plastic stent would be placed to minimise the risk of ERCP-induced cholangitis.
If a malignant-appearing stricture of the bile duct or pancreatic duct was seen by ERCP, an attempt at cytologic or tissue diagnosis by brush cytology, transpapillary FNA and/or biopsy would be made.
If a stent was placed for malignancy, a plastic stent would be placed initially and changed by ERCP at a later date to a metallic stent if subsequent evaluation showed that the patient was not an operative candidate and had a potential
